-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to a CBS report on April 10, eight people in Georgia, the United States, experienced adverse reactions after being injected with Johnson & Johnson's new crown vaccine.
It is understood that the European Medicines Agency (EMA) issued an announcement on the 9th that 4 cases of abnormal thrombosis accompanied by thrombocytopenia were found among the vaccinators of Johnson & Johnson vaccine, and 1 of them died as a result.
Although the United States did not disclose more adverse reactions, the European Union revealed that the Johnson & Johnson vaccine may cause thrombosis.
However, on the same day as the EMA announcement, Johnson & Johnson also issued a statement stating that it had closely followed up and investigated the side effects of the vaccine.
In fact, this is not the first "vaccine turmoil" that Johnson & Johnson has fallen into.
And before Johnson & Johnson, another adenovirus vaccine of the same type that has received much attention, AstraZeneca, has also been turbulent due to thrombosis, and was even banned by many countries at one time.
At present, Johnson & Johnson vaccine is only vaccinated in the United States.
